NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A class action securities lawsuit has been filed against WPP plc, alleging securities fraud that negatively impacted investors between February 27, 2025, and July 8, 2025 [1][2] Company Performance - The lawsuit claims that WPP provided overly positive statements while concealing material adverse facts about its media arm's ability to handle macroeconomic challenges and competition, leading to a significant loss of market share [2] - On July 9, 2025, WPP reported a deterioration in performance for Q2 2025, attributing this to macroeconomic uncertainty affecting client spending and weaker new business, compounded by ongoing restructuring within WPP Media [2] - Following the trading update, WPP's stock price fell from $35.82 per share on July 8, 2025, to $29.34 per share on July 9, 2025, marking a decline of approximately 18.1% in one day [2] Legal Proceedings - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky has a history of securing substantial settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4]

Core Viewpoint - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1][2]. Group 1: Lawsuit Details - The class action lawsuit aims to recover losses for aTyr investors affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [1]. - The complaint alleges that defendants made positive statements about Efzofitimod while concealing material adverse facts regarding its efficacy, particularly its ability to allow patients to taper steroid usage [2]. - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in a stock price decline from $6.03 to $1.02, an 83.2% drop in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Levi & Korsinsky Urges Primo Brands Corporation / Primo Water Corporation (PRMB) Shareholders to Act Before Lead Plaintiff Deadline January 12, 2026November 14, 2025 3:55 PM EST | Source: Levi & Korsinsky, LLPNew York, New York--(Newsfile Corp. - November 14, 2025) - If you suffered a loss on your Primo Brands Corporation / Primo Water Corporation (NYSE: PRMB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:h ...

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected shareholders between March 10, 2024, and September 29, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding their drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [3]. - Allegations include that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over traditional monoclonal antibodies [3]. Group 2: Next Steps for Shareholders - Shareholders who experienced losses during the specified timeframe are encouraged to seek information on their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a well-established securities litigation firm, has a strong track record in securing recoveries for shareholders and has been recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for alleged securities fraud affecting shareholders between August 6, 2024, and August 4, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that the company made false statements regarding the launch of its new product, Inspire V, which was reportedly unsuccessful due to poor demand and excess inventory at treatment centers [3]. - Allegations include that Inspire Medical Systems failed to complete essential tasks for a successful product launch, such as training for treatment center customers, setting up IT systems, and ensuring proper Medicare reimbursement [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who experienced losses during the specified timeframe are encouraged to seek information on their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a history of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [5].

Core Viewpoint - A class action securities lawsuit has been filed against CarMax, Inc. alleging securities fraud that affected shareholders between June 20, 2025, and September 24, 2025 [2][3] Group 1: Lawsuit Details - The lawsuit claims that CarMax's management made false statements regarding the company's growth prospects, suggesting that the growth in the 2026 fiscal year was misleadingly attributed to temporary factors such as customer speculation about tariffs [3] - The complaint asserts that the statements made by the defendants about CarMax's business operations and future prospects were materially false and lacked a reasonable basis during the relevant time [3] Group 2: Next Steps for Affected Shareholders - Shareholders who experienced losses in CarMax stock during the specified period are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4] Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a strong track record of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the United States for seven consecutive years [5]

Core Viewpoint - A securities fraud class action has been filed against Synopsys, Inc. following disappointing Q3 2025 financial results, which were attributed to underperformance in its IP business [1][2]. Group 1: Legal Action and Investigation - The class action lawsuit seeks to represent investors who acquired Synopsys securities between December 4, 2024, and September 9, 2025 [1][3]. - The lawsuit was prompted by a significant drop in Synopsys' share price, which fell by $216.59, or 35%, on September 10, 2025, after the company reported poor financial results [2][5]. - Hagens Berman, a national shareholders rights firm, is investigating claims that Synopsys misled investors regarding customer risks and growth prospects [2][6]. Group 2: Financial Performance - Synopsys reported Q3 2025 earnings per share (EPS) of $1.50, representing a 45% decline year-over-year and a 33% decline sequentially [5]. - The company experienced nearly an 8% decline in Design IP revenues compared to the prior year quarter [5]. - The results led to the largest single-day percentage decline in Synopsys' stock since its IPO in 1992 [5]. Group 3: Business Operations and Strategy - Synopsys operates in two reportable segments: Design IP and Design Automation [3]. - The lawsuit alleges that Synopsys made false statements and failed to disclose critical information about its business, particularly regarding the impact of increased focus on AI customers on the economics of its Design IP business [4][5]. - The company acknowledged the need to pivot its IP resources and roadmap to focus on the highest-growth opportunities [5].